Entecavir

證據等級: L5

預測適應症: 10 個

Entecavir: From Chronic Hepatitis B to Chronic Hepatitis C Virus Infection

One-Sentence Summary

Entecavir is a potent guanosine nucleoside analogue approved globally for the treatment of chronic hepatitis B virus (HBV) infection, where it inhibits HBV DNA polymerase to suppress viral replication. The TxGNN model predicts it may be effective for Chronic Hepatitis C Virus Infection with a score of 99.98%, and evidence searches retrieved 40 clinical trials and 20 publications — however, none of these directly demonstrate Entecavir anti-HCV efficacy; all evidence pertains to HBV management in co-infection contexts. The prediction is assessed as a knowledge-graph false positive rather than a genuine repurposing signal.

Quick Overview

Item	Content
Original Indication	Chronic Hepatitis B Virus Infection (globally approved; not registered in New Zealand)
Predicted New Indication	Chronic Hepatitis C Virus Infection
TxGNN Prediction Score	99.98%
Evidence Level	L4
New Zealand Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Entecavir is a guanosine nucleoside analogue. After intracellular triphosphorylation, it competitively inhibits HBV DNA polymerase and blocks three critical steps of viral replication: polymerase priming, reverse transcription of pregenomic RNA (pgRNA), and DNA-dependent DNA synthesis. It is a globally recognised first-line therapy for chronic HBV with a high genetic barrier to resistance, confirmed by multiple completed Phase 3 RCTs.

The TxGNN model assigns a high prediction score (99.98%) for chronic HCV infection due to the proximity of HBV and HCV disease nodes within the knowledge graph — both viruses cause chronic hepatitis, share transmission routes (blood-borne, sexual), and frequently co-infect the same patient populations. This structural adjacency creates a spurious co-occurrence signal that the model cannot distinguish from a true mechanistic relationship.

The mechanistic basis for this prediction is absent. HCV is a positive-strand RNA virus that replicates exclusively via its NS5B RNA-dependent RNA polymerase — a fundamentally different enzyme from HBV's DNA polymerase (reverse transcriptase). Entecavir has no known inhibitory activity against HCV NS5B. Every clinical trial and publication retrieved in this search represents Entecavir managing the HBV component in co-infected patients or being co-administered with direct-acting antivirals (DAAs) for HCV, not acting directly against HCV itself. This is a confirmed knowledge-graph false positive and not a clinically actionable repurposing signal.

More Actionable Signal — Rank 2 (Hepatitis B Virus Infection): Entecavir's own approved indication appears as the second-ranked prediction (TxGNN score 99.85%, Evidence Level L1, Decision: Proceed with Guardrails). This reflects Entecavir's well-established efficacy for HBV infection supported by robust Phase 3 RCT data. For New Zealand, the relevant regulatory question is potential Medsafe registration for HBV — not HCV repurposing.

Clinical Trial Evidence

All trials below were retrieved with the query Entecavir + chronic HCV infection. None directly assess Entecavir as an anti-HCV agent. They represent its role in HBV management among patients receiving HCV treatment, or general HBV efficacy trials captured by co-infection search overlap.

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02555943	Phase 2/3	Completed	23	Prospective study on HBV reactivation incidence during DAA anti-HCV treatment in HCV/HBV co-infected patients; Entecavir used for HBV suppression — no direct HCV efficacy assessment
NCT04405011	N/A	Unknown	60	Three-arm RCT examining whether prophylactic nucleoside analogue (NUC) prevents HBV reactivation during DAA therapy for chronic HCV; evaluates HBV management, not Entecavir anti-HCV activity
NCT03662568	Phase 1	Completed	56	Drug-drug interaction study of Morphothiadine Mesilate/Ritonavir (anti-HCV) with Entecavir or TDF in healthy subjects; safety of co-administration only
NCT00065507	Phase 3	Completed	195	Entecavir 1.0 mg vs Adefovir in HBV-infected patients with hepatic decompensation over 96 weeks; HBV-focused, HCV not the study target
NCT01020565	Phase 2	Completed	60	Entecavir antiviral activity and safety in Japanese HBV patients (0.1 mg and 0.5 mg for 52 weeks); HBV-focused pharmacokinetic study
NCT00412529	Phase 3	Completed	44	Exploratory comparison of Telbivudine vs Entecavir viral kinetics in HBeAg-positive compensated CHB over 12 weeks; HBV kinetics study
NCT00096785	Phase 3	Completed	69	Entecavir vs Adefovir early viral load reductions in nucleoside-naive HBV adults; HBV efficacy comparator trial
NCT01270178	N/A	Unknown	420	Prospective Entecavir trial for chronic HBV in HCC patients post-radiofrequency ablation; evaluates tumour recurrence prevention, not HCV therapy
NCT00371150	Phase 4	Completed	131	Observational study of Entecavir antiviral effect in Black/African-American and Hispanic populations with nucleoside-naive chronic HBV; ethnicity-specific efficacy data
NCT01928511	Phase 4	Completed	254	Switch or add PEG-interferon in chronic HBV patients on long-term nucleoside therapy (SWAP Trial); evaluates HBsAg clearance strategies

Literature Evidence

PMID	Year	Type	Journal	Key Findings
36146665	2022	Cohort	Viruses	HCV reactivation observed in anti-HCV antibody-positive CHB patients receiving nucleoside analogue (Nuc) therapy; Entecavir suppresses HBV while HCV may reactivate — highlights co-infection complexity
28230928	2017	Cohort	J Gastroenterol Hepatol	HBV reactivation risk during DAA therapy for chronic HCV; nucleoside analogue prophylaxis (including Entecavir) recommended to prevent HBV rebound
24773464	2014	Review	Expert Opin Pharmacother	HBV/HCV co-infection treatment: Entecavir for HBV component; DAAs for HCV — separate mechanistic targets
25027705	2014	Review	Minerva Gastroenterol Dietol	FDA-approved antivirals for HBV (including Entecavir) and HCV reviewed alongside renal effects; no crossover anti-HCV activity reported for Entecavir
32173307	2020	Review	Clin Res Hepatol Gastroenterol	HBV and HCV management in children; Entecavir cited as HBV therapy — no HCV indication discussed
22959099	2013	Review	Clin Res Hepatol Gastroenterol	HBV/HCV co-infection as therapeutic challenge; case report illustrates complexities of managing both viruses with distinct drug classes
35327336	2022	Review	Biomedicines	Therapy of chronic viral hepatitis (HBV/HCV/HDV); Entecavir and Tenofovir for HBV suppression; DAAs for HCV — mechanistically distinct treatments
16937041	2006	Review	Wien Med Wochenschr	Early overview of chronic hepatitis B and C treatment; Entecavir emerging as potent HBV option with no anti-HCV role
38450508	2024	Review	Rev Esp Enferm Dig	Hemophilia and hepatology: Entecavir/Tenofovir for HBV (approved 2005–2008) and DAAs for HCV (approved 2015) marked as independent treatment milestones
36873880	2023	Case Report	Front Med	Unusual viral evolution in concurrent HBV/HCV infection: anti-HBV therapy (Entecavir) suppresses HBV but may unmask latent HCV — demonstrates viral interaction, not anti-HCV activity

New Zealand Market Information

Entecavir is not currently registered with Medsafe and holds no authorizations in New Zealand. No approved indication text is available from local regulatory records.

For reference, Entecavir (brand name Baraclude) is approved in major markets including the United States (FDA, 2005), the European Union, Japan, and Taiwan for the treatment of chronic HBV infection in adults with evidence of active viral replication and liver disease.

Safety Considerations

Please refer to the package insert for safety information.

Critical Safety Note for HIV/HBV Co-infected Patients: Although Entecavir is approved for HBV and not for HIV treatment, published evidence (PMID 17582071, 18453854) demonstrates that Entecavir has partial anti-HIV-1 reverse transcriptase activity. Use of Entecavir as HBV monotherapy in HIV-positive patients not on full antiretroviral therapy (ART) can select for the HIV M184V resistance mutation, compromising future HIV treatment options. This "Entecavir surprise" phenomenon is an important prescribing guardrail in co-infected populations.

Conclusion and Next Steps

Decision: Hold (for the chronic HCV indication)

Rationale: The TxGNN prediction of Entecavir efficacy against chronic HCV infection is a mechanistic false positive. HCV is an RNA virus relying on NS5B RNA-dependent RNA polymerase for replication — an enzyme Entecavir does not inhibit. Zero clinical trials in the evidence base demonstrate direct anti-HCV activity for Entecavir, and no biological rationale supports further investigation in this direction.

To proceed, the following is needed:

No further investigation is recommended for the HCV indication — the mechanistic mismatch is definitive and cannot be resolved by additional evidence gathering
The actionable signal is Rank 2 (Hepatitis B Virus Infection, Decision: Proceed with Guardrails): Entecavir's globally established HBV indication is supported by multiple completed Phase 3 RCTs (L1 evidence); if NZ registration or PHARMAC listing is under consideration, this is the appropriate pathway to pursue
Full package insert safety data (warnings, contraindications, black-box warnings if applicable) must be obtained before any regulatory submission
For HIV/HBV co-infected patients, a clinical protocol ensuring concurrent ART coverage must be in place before Entecavir is initiated
A pharmacoeconomic comparison with existing NZ-approved HBV therapies (e.g., Tenofovir) would be required to support PHARMAC funding consideration
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.